HRAS and cancer: Knockdown studies showed that the non-mutated WT RAS genes are necessary for growth-factor-mediated signaling to RAS effector pathways in HRAS-, NRAS, and KRAS-mutated cancer cells [30,50], indicating that cancer cell response to growth factors may be mediated by WT RAS, not the oncogenic RAS mutant.